Dividing T cells: A potential target for improving cancer immunotherapy

When an immune T cell divides into two daughter cells, the activity of an enzyme called mTORC1, which controls protein production, splits unevenly between the progeny, producing two cells with different properties. Such ‘asymmetric division,’ uncovered by researchers using lab-grown cells and specially bred mice, could offer new ways to enhance cancer immunotherapy and may have other implications for studying how stem cells differentiate.